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Introduction
Genetic variation is common across the human 
genome. It is estimated that there are more than 7 million 
single nucleotide polymorphisms (SNPs) with a minor 
allele frequency of 5% to 10%. Although most SNPs are 
not functionally important, there is a subset of variants 
that alter the expression or function of a gene product 
(Banu et al., 2011). 
Human tumour necrosis factor alpha (TNFα) gene 
is located in the MHC locus at region 6 on chromosome 
6p21.3 (http://omim.org/entry/191160). Tumor necrosis 
factor alpha (TNF α) is one of the most important cytokines 
in the inflammation. It effects both tissue destruction and 
repairment (Black et al. 1997). Not only mechanisms 
reducing the tendency to neoplastic transformation but 
also the mechanisms creativing neoplastic transformation 
tendency are stimulated by effect of TNFα (Wajant et 
al., 2003). While some studies showed that high levels 
of TNFα suppresses the tumor angiogenesis in malign 
tissues, the other studies showed that TNF α may act as 
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Abstract
 It is not clear how gene polymorphisms affecting drugs can contributes totheir efficacy in multiple 
myeloma (MM). We here aimed to explore associations among gene polymorphisms of tumor necrosis factor 
alpha (TNFalpha), nitric oxide synthesis 3 (NOS3) and multi-drug resistance 1 (MDR1), clinical parameters, 
prognosis and survival in MM patients treated with VAD (vincristine-adriamycine-dexamethasone), MP 
(mephalane-prednisolone), autolougus stem cell transplantation (ASCT), BODEC (bortezomib-dexamethasone-
cyclophosphamide) and TD (thalidomide-dexamethasone). We analyzed TNFalpha, NOS 3 and MDR1 in 77 
patients with MM and 77 healthy controls. The genotyping was performed with PCR and/or PCR-RFLP. There 
was no clinically significant difference between MM and control groups when TNFalpha (-238) and (-857) and 
MDR1 gene polymorphisms were studied. However, the TNFalpha gene polymorphism (-308) GG genotype 
(p=0.012) and NOS3 (+894) TT genotype (p=0.008) were more common in the MM group compared to healthy 
controls. NOS3 (VNTR) AA (p=0.007) and NOS3 (+894) GG genotypes (p=0.004) were decreased in the MM 
group in contrast. In conclusion, the NOS3 (+894) TT and TNFalpha (-308) GG genotypes may have roles in 
myeloma pathogenesis. 
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an endogenous tumor growth factor (Wajant et al., 2003). 
In most studies, It was shown to be a strong association 
between TNFα and hematologic and non-hematologic 
malignancy (Black et al. 1997; Wajant et al., 2003; Olmos 
and Llado, 2014). 
Nitric oxide (NO) is synthesized with the oxidation 
of L-arginin by nitric oxide synthase (NOS) (Dogra 
and Khullar, 2013). There are three isoforms of NOS: 
neuronal NOS (nNOS), endothelial NOS (eNOS) and 
immunological NOS (iNOS) (Nathan and Xie, 1994). 
eNOS on chromosome 7q 35-36 takes an important role 
in homeostasis (Bivalacqua et al., 2002). Therefore, 
variations on this gene may result in decrease of NO 
synthesis and cause several diseases (Heil et al., 2006; 
Game et al., 2013). Drug resistance is the main reason 
of anti-cancer treatment failure. P-glycoprotein is the 
main influence of multi drug resistance gene (Juliano 
and Ling, 1976). MDR1 phenotype is defined as over 
expression of MDR1 gene to produce 170 kDa protein 
and p-glycoprotein (Germann, 1996). Over expression of 
p-glycoprotein leads to efflux of the drugs (Jamroziak et 
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al., 2005). More than 50 single nucleotide polymorphism 
is defined for MDR1 gene. The most known polymorphism 
of MDR1 gene is MDR1 C3435T and it is a significant 
prognositic factor for acute lymphoblastic leukemia 
(Jamroziak et al., 2005). 
Scientists still do not know exactly what causes most 
cases of multiple myeloma. However, they have made 
progress in understanding how certain changes in DNA 
can make plasma cells become cancerous (http://www.
cancer.org/cancer/multiplemyeloma/). Multiple myeloma 
(MM) is a B-lymphoid cell disease with increased number 
of plasma cells in the bone marrow. It is characterized 
with overproduction of monoclonal immunoglobulin, 
osteolytic bone lesions, hypercalcemia, anemia and renal 
failure (Kyle, 1994; Knop, 2014). Radiation, viral agents, 
chronic antigenic stimulation and environmental factors 
are described as the etiology of disease (Ichimaru et al., 
1982). 
Genetic factors including single nucleotide 
polymorphisms (SNPs) that change cytochrome P450 
(CYP) activity and epigenetic regülation that modifies 
CYP expression levels may contribute to the change in 
pharmocokinetics and adverse drug reactions (ADRs) 
(Nakamura et al., 2013). In this study, we investigated 
relationship between TNFα, NOS3, MDR1 genes 
polymorphisms and clinical parameters, prognosis 
and survival for the VAD (Vincristine-Adriamycine-
Dexamethasone), MP (Mephalane-Prednisolone), 
autologous stem cell transplantation (ASCT), BODEC 
(Bortezomib-Dexamethasone-Cyclophosphamide) and 
TD (Thalidomide-Dexamethasone) treatment of multiple 
myeloma.
Materials and Methods
The study was approved by the Local Ethics 
Committee. Of 77 patients with Multiple Myeloma, 46 
of the patients enrolled to the study were male, 31 of 
Table 1. Clinical Features and Treatment Regimes of Multiple Myeloma Patients
  Multiple Myeloma Control
  Median na      (%) na       (%)
Age
  59    (31-81)  45      (20-66)
Gender
 Female/Male  31/46    (40/60) 38/39 (49/51)
Ig subtype
 k/l  54/23    (70/30) 
 G/A  48/15    (62/20) 
 Ligth chain  14         (18) 
Stage (Salmon-Durie)
 II/III  12/65    (16/84) 
 A/B  55/22    (71/29) 
IPI
 I  19         (25) 
 II/III  36/22    (46/29) 
ECOG
 >1   32         (42) 
Hemoglobin
 gr/dL 9.8    (6.0-14.8)  
Leukocyte
 μL 6500 (1290-17300)  
Platelets
 103/μL 170   (26-700)  
C-reactive protein
 mg/dL 6.25  (2.9-70)  
LDH
 IU/L 390   (164-2540)  
b2-mikroglobulin
 mg/L 4.2    (1.7-27)  
Albumin
 gr/L 3.3    (1.6-5.2)  
Treatment (n=66)
 1. line (VAD, MP)  60/6 
 2. line (ASCT, BODEC, TD)  18/21/15 
 3. line (ASCT, BODEC, TD)  8/15/3 
Mortality
   21        (32) 
Median follow-up (month)
  26.4 (6.1-85.2)
 n=77; VAD, vincristine, adriamycin ve dexamethasone; MP, melphalan, prednisolone; BODEC, bortezomib, dexamethasone, cyclophosphamide; 
TD, thalidomide, dexamethasone; ASCT, autologous stem cell transplantation; ECOG, performance status; LDH, lactic dehydrogenase, IPI; 
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the patients were female. Median age was 59 (31-81 
years) with the diagnosis and under treatment for MM in 
the Hematology Clinic, Gaziantep University Hospital. 
Seventy seven healthy controls were enrolled to this 
study, 39 of the controls were male, 38 were female and 
the median age was 45 (20-66 years).
Polymorphism analysis
DNA samples were isolated from peripheral blood 
in the healthy control group and from bone marrow in 
the patient group. Cytokine Genotyping was performed 
by polymerized chain reaction (PCR) or polymerized 
chain reaction restriction fragment length polymorphism 
(PCR-RFLP) (Akcali et al., 2010). Single nucleotide 
polymorphisms of the TNF α (-308,-238,-857), NOS3 
(VNTR,-894) and MDR1 gene were analyzed by the 
amplifications of PCR products in gel electrophoresis.
Statistical analysis
The analyses of data’s were performed by using 
the software SPSS (Statistical Package for the Social 
Sciences) for Windows (Version 13.0; SPSS, Chicago, 
IL). The statistical significance of differences between 
the patient and control groups was estimated by logistic 
regression analysis. Adjusted odds ratios (ORs) were 
calculated with logistic regression model that controlled 
for gender and age and were reported at 95% confidence 
intervals. Differences in TNF α (-308, -238, -857), NOS3 
(-894) and MDR1 allele frequency between the control 
group and the patient group were compared by using the 
X2 test, and when needed, Fisher exact test was used. 
Survival probabilities were estimated by The Kaplan-
Meier method and differences were compared using the 
log rank test (Kaplan and Meier, 1958). The Cox stepwise 
regression analysis was employed to confirm significance 
of risk factors (Cox, 1972). In multivariate analysis, 
we used eliminated variables stepwise (backward) by 
significance of less than 10%. P-values <0.05 were 
considered to indicate statistical significance.
Results 
Patients who were followed up for at least 6 
months after the first line treatment were analyzed for 
response status and overall survival. Sixty of these 
patients received VAD (Vincristine-Adriamycine-
Dexamethasone) treatment regime and 6 patients received 
MP (Mephalane-Prednisolone) treatment regime as the 
first line chemotherapy. Eighteen patients underwent 
autologous stem cell transplantation (ASCT), 21 
patients received BODEC (Bortezomib-Dexamethasone-
Cyclophosphamide) treatment regime and 15 patients 
received TD (Thalidomide-Dexamethasone) treatment 
regime as the second line therapy for treatment-resistance. 
Eight of the patients underwent ASCT, 15 received 
BODEC treatment regime and 3 received TD treatment 
regime for the third line therapy. The mean follow up 
was 26,4 (6,1-85,2) months and mortality ratio was 32% 
(Table 1).
The immunoglobulins (Ig) subtypes of the patients 
were detected as light chain 14 (18%), IgG 48 (62%), 
IgA 15 (20%), kappa 54 (70%) and lambda 23 (30%). 
According to Salmon-Durie classification 12 patients 
were stage II (16%) and 65 patients (84%) were stage 
III. Also 55 patients were phase A and 22 patients were 
phase B. According to International Staging System; 19 
Table 2. Comparison of Frequencies of NOS3 (+894 ve VNTR), MDR1 and TNF Α Gene Polymorphisms Between 
Patients with Multiple Myeloma And Healthy Controls
Genotip MM Saglıklı Kontrol OR %95 CI P
na (%) na (%)
NOS3 (VNTR)
AA 40 (51.9) 57 (74.0) 0.075* 0.011-0.499* 0.007*
AB 28 (36.4) 18 (23.4) 0.167* 0.024-1.165* 0.071*
BB 9 (11.7) 2 (2.6) 0.201& 0.042-0.965& 0.056&
NOS3 (+894)
GG 37 (48.1) 51 (66.2) 0.041* 0.005-0.365* 0.004*
GT 25 (32.5) 25 (32.5) 1.000& 0.509-1.963& 1.000&
TT 15 (19.4) 1 (1.3) 0.049* 0.005-0.450* 0.008*
MDR1
CC 19 (24.7) 15 (19.5) 1.585* 0.621-4.047* 0.335*
CT 31 (40.3) 25 (32.5) 1.359* 0.607-3.043* 0.456*
TT 27 (35.0) 37 (48.0) 1.713* 0.897-3.272* 0.141*
TNFα (-308)
AA 0 0
AG 18 (23.4) 35 (45.6) 0.368* 0.169-0.803* 0.012*
GG 59 (76.6) 42 (54.4)
TNFα (-238)
AA 0 0
AG 13 (16.9) 10 (13.0) 0.883* 0.311-2.507* 0.815*
GG 64 (83.1) 67 (87.0) 0.635& 0.274-1.476& 0.387&
TNFα (-857)
TT 16 (20.8) 11 (14.3) 0.985* 0.349-2.778* 0.977*
TC 28 (36.4) 25 (32.5) 1.137* 0.407-3.181* 0.806*
CC 33 (42.8) 41 (53.2)
an=77, *:OR; Odds ratio (%95CI) age and sex adjusted, &Fisher’s Exact Test
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of the patients (25%) were stage I, 36 (46%) were stage 
II and 22 (29%) were stage III. And according to Eastern 
Cooperative Oncology Group (ECOG) performance scale 
32 of the patients (42%) have higher score than 1 (Table 
1). The mean hemoglobine levels, leucocyte counts, 
thrombocyte counts, c-reactive protein (CRP), lactate 
dehidrogenase (LDH), B2-microglobuline and albumine 
levels were 9,8 (6-14,8) gr/dl, 6500 (1290-17300) /mm3, 
170x103 (26-700x103), 6,25 (2,9-70) mg/dl, 390 (164-
2540) IU/L, 4,2 (1,7-27) mg/L, 3,3 (1,6-5,2) gr/L (Table 1).
TNFα, NOS3 and MDR1 gene polymorphisms 
of 77 MM patients and comparative results with the 
control group were summarized in Table II. In NOS3 
gene VNTR polymorphism group, the AA subgroup was 
significantly lower in MM group in contrast to the control 
group (p=0,007, OR=0,075). When we determined NOS 
gene (+894) polymorphism results, GG genotype was 
significantly lower (p=0,004, OR=0,041) and TT genotype 
was significantly higher (p=0,008, OR=0,049) in MM 
group. For MDR1 gene polymorphism, there was no 
significant difference between patient and control groups. 
For TNFα gene (-308) polymorphism, GG genotype was 
statistically significant higher in MM group (p=0,012, 
OR=0,368) and AG genotype was statistically significant 
lower in MM group (p=0,012, OR=0,368). But there 
was no difference both (-238) and (-857) polymorphisms 
between control and patient groups (Table 2). 
Six years overall survival was 65 months for the sixty 
six patients who were enrolled to the study with at least 6 
months follow up and 6 years event free survival was 34,5 
months, respectively. There was no significant difference 
between NOS3, TNFα and MDR1 gene polymorphism 
compared with the factors which have impact on overall 
survival such as gender, age, stage, ECOG, LDH, CRP, 
first line treatment and response to first line treatment. In 
26 patients with Salmon-Durie stage II and in 40 patients 
with stage III, 6 years OS was 84 months and 56,3 months, 
respectively (p=0,055). Overall survival results in patient 
groups due to ISS were analyzed in 19 patients with stage 
I was 70 months, in 27 patients with stage II was 61 
months and in 20 patients with stage III was 56,3 months 
(p=0,033) . According to ECOG; 53 patients were ≤1 and 
their overall survival ratio was 73,2 months. Twenty three 
patients were ECOG >1 and their overall survival was 
53,2 months (p=0.018).
Discussion
In multiple myeloma (MM), TNF α is involved in 
the generation of malignant plasma cells, as monoclonal 
plasma cells were produced when mononuclear cells 
from myeloma patients were exposed to TNF α and 
interleukin-4 in vitro (Neben et al., 2002). A study from 
Hungary, in 94 MM patient and 141 control group revealed 
us, A allele of TNF α (-308) is lower expressed in MM 
patients. And this result can be interpreted as A allele 
may have a preventive effect from the disease (Kadar 
et al., 2008). But; in another study, TNF α (-308) gene 
polymorphism and disease severity compared between 
69 MM patient and 102 healthy control group.There was 
no relation between MM and this gene polymorphisms 
(Iokupova et al., 2003). In our study genotypes of TNF α 
(-308) polymorphism are distributed as; AA 0 (0%), AG 18 
(23,4%), GG 59 (76,6%) (Table 2). The over expression of 
GG genotype in MM group versus control group (p=0.012) 
may prone to MM development. But there is no association 
between GG genotype of TNF α (-308) polymorphism 
and response to first line treatment, overall survival of 
ASCT-Thalidomide-Bortezomib, 6 years overall survival 
and 6 years event free survival.
In a study, it is reported that GG genotype of TNFα 
(-238) polymorphism may be related to early progression 
in 168 MM patients formerly treated with thalidomide 
based regimens (Du et al., 2009). In another study, 81 
refractory/relapsed MM patients treated with thalidomide 
based regimens were analyzed. Both TNFα (-308, -238) 
polymorphisms and TNFα cytokine levels were measured. 
The patients with G allele of TNFα (-238) has been found 
to have a shorter progression free survival. And also 
cytokine levels were lower before treatment (p=0,047). 
GG allele is also found to be related with early progression 
but it has no effect on overall survival (Neben et al., 2002). 
In our study genotypes of TNFα (-238) are distributed as; 
AA 0 (0%), AG 13 (16,9%), GG 64 (83,1%). There is no 
statistically significant relation between MM patient and 
control group. And there is no association between TNF α 
(-238) polymorphism and response to first line treatment, 
overall survival of ASCT-Thalidomide-Bortezomib, 6 
years overall survival and 6 years event free survival.
Genotypes disturbances of TNFα (-857) polymorphism 
are as; TT: 16 (20.8%), TC: 28 (36.4%), CC: 33 (42.8%). 
No significant difference is detected between MM patients 
and controls for TNF α (-857) polymorphism. And there 
is no association between TNF α (-857) polymorphism 
and response to first line treatment, overall survival of 
ASCT-Thalidomide-Bortezomib, 6 years overall survival 
and 6 years event free survival.
There are several studies about relationship between 
NOS3 (+894, VNTR) polymorphism and several solid 
tumors such as breast, ovarian, colorectal, prostate and 
vulvary tumors. In one study, there was no relation 
between breast cancer and NOS3 (Ghilardi et al., 2003) 
but in another study, researchers suggested that NOS3 
(+894) polymorphism increases nearly two-fold risk of 
the breast cancer without the affect of any other clinical 
parameter (Hefler et al., 2006). There are a few studies 
analyzing hematological malignancies and NOS3 
(+894) polymorphism in the literature. While there was 
no statistically significant result between non-Hodgkin 
lymphoma and NOS3 (+894) polymorphism (Wang 
et al., 2006). In our study, the distribution of NOS3 
(+894) polymorphism of MM patients were detected GG 
genotype 37 patients (48.1%), GT genotype 25 (32,5%), 
TT genotype 15 (19,4%) respectively (Table 2). Lower 
expression of GG genotype (p=0,004) and over expression 
of TT genotype in MM patients (p=0,008) may predispose 
to disease. GG genotype may have a protective role on 
this disease. It is known that, when there is mutant T allele 
in NOS3 (+894) polymorphism, it may affect functions 
of the proteins that have different functions in the body 
(Hefler et al., 2002). In our study, TT genotype of NOS3 
(+894) polymorphism is over expressed in MM group 
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versus control group (19.4% vs 1.3%). The results may 
attract attention an unknown role of this genotype in the 
pathogenesis of MM. Unfortunately, we could not find 
a statistically significant result between TT genotype 
of NOS3 (+894) polymorphism and response to first 
line treatment, overall survival of ASCT-Thalidomide-
Bortezomib treatments, 6 years overall survival and 6 
years event free survival.
Some studies showed that A allel of NOS3 (VNTR) 
gene is related with metastasis of prostate cancer and 
poor prognosis in patients with ovarian or vulvary 
cancer (Medeiros et al., 2002, Riener et al., 2004). In 
our study, genotypes of NOS3 (VNTR) polymorphism 
were distributed as; AA 40 (51,9%), AB 28 (36,4%) and 
BB 9 (11.7%). The lower expression of AA genotype 
in MM is statistically significant (p=0.007) and may 
be related to a protective effect from disease. In NOS3 
(VNTR) polymorphism; B is the normal allele and A is the 
mutated allele. And lower expression of AA genotype of 
NOS3 polymorphism and changes in mRNA expression 
may have a role in MM pathogenesis. Still there is no 
association between AA genotype of NOS3 polymorphism 
and response to first line treatment, overall survival of 
ASCT-Thalidomide-Bortezomib, 6 years overall survival 
and 6 years event free survival.
The polymorphisms of MDR1 gene have correlation 
with prognosis of MM patients. The patients carrying 
homozygote T allele, heterozygote/homozygote C allele 
of C3435T position have worse prognosis (Drain et al., 
2009). In an Italian study, 110 MM patients with TT 
genotype of MDR1 polymorphism have better survival 
(Buda et al., 2007). Buda et al. (2010) said that the T/T 
allele carriers might be expected to show a better response 
to chemotherapy in the MDR1 C3435T SNP. In our study, 
genotypes of MDR1 polymorphism are distributed as; TT 
27 (35%), CT 31 (40.3%), CC 19 (27.3%). There was no 
significant difference between patient and control group 
(Table 2). And there is no association between MDR1 
polymorphism and response to first line treatment, overall 
survival of ASCT-Thalidomide-Bortezomib, 6 years 
overall survival and 6 years event free survival.
When we compare clinical features and factors that 
affect prognosis (Age, stage (Salmon-Durie and IPI), Ig 
subtype, ECOG, Platelet count, LDH and CRP levels, 
6-year event free survival and 6-year overall survival), the 
patients with IPI-3 have shorter overall survival compared 
to patients with IPI 1 and 2 (p=0.004) and also the patients 
with lower platelet count (<150 x 10³/ml) have worse 
overall survival (p=0.013). There is a significant relation 
between platelet count and overall survival (Table 1). 
In conclusion, in this study, six of the MM patients 
who were refractory after the first line treatment, have 
GG genotype of TNFα (-238) gene polymorphism. This 
polymorphism may be related to poor prognosis and 
responsiveness to treatment. And also we found that TT 
genotype of NOS3 (+894) polymorphism and GG genotype 
of TNFα (-308) polymorphism are important biomarker 
in MM patients. We suggest that these polymorphisms 
may have a role in the pathogenesis of this disease. At 
the same time, our results also showed a relation between 
GG genotype of TNF α (-238) polymorphism and early 
progression. 
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